May 05, 2011, 05.43 PM | Source: Moneycontrol.com
Strides Arcolab Thursday said it has got approval from US Food and Drug Adminstrator for its general anesthetic injection, Midazolam in multiple-dose vials.
The pharmaceutical company has got approval to market Midazolam injection of 1 mg/ml packaged in 10mg/10 ml multiple-dose vials and 5mg/ml packages in 25 mg/5ml and 50 mg/10ml multiple-dose vials.
Midazolam Injection will be launched in the third quarter of 2011-12, in partnership with US-based Sagent Pharmaceuticals and aims to address over 95% of the sterile injectable market for Midazolam in the US.
The total market for Midazolam in the USA is about USD 51 million, according to IMS September 2010 data, the company said in a press release to the stock exchanges.
At 13:50 hrs, shares of Strides Arcolab was trading at Rs 389.35, down 1% on the Bombay Stock Exchange.
Strides Shasun stock price
On May 04, 2016, Strides Shasun closed at Rs 1109.90, down Rs 12.8, or 1.14 percent. The 52-week high of the share was Rs 1412.45 and the 52-week low was Rs 848.00.
The company's trailing 12-month (TTM) EPS was at Rs 20.56 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 53.98. The latest book value of the company is Rs 168.35 per share. At current value, the price-to-book value of the company is 6.59.
Strides Shasun | Bharti Airtel | Idea Cellular | J
A regulatory filing by Strides Shasun in March had
Ashwani Gujral of ashwanigujral.com recommends sel
"The company's wholly-owned subsidiary Strides Pha
Ashwani Gujral of ashwanigujral.com recommends buy
Strides Shasun has informed regarding a press rele
HeidelbergCement India has reported a sales turnov
Medi-Caps has reported a sales turnover of Rs 6.77